Apexigen Inc

Change company Symbol lookup

Select an option...

APGN Apexigen Inc

NSRGY Nestle SA

WE WeWork Inc

NOK Nokia Oyj

HLNE Hamilton Lane Inc

SAL Salisbury Bancorp Inc

MFON Mobivity Holdings Corp

XPEV Xpeng Inc

ENVX Enovix Corp

COGT Cogent Biosciences Inc

Go

Apexigen, Inc., formerly Brookline Capital Acquisition Corp., is a clinical-stage biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. It has a diversified pipeline of wholly owned and partnered assets leveraging its APXiMAB antibody discovery platform. The Company’s pipeline of immuno-oncology therapeutic candidates is led by sotigalimab, which is in Phase II clinical development, and also includes several preclinical stage immuno-oncology programs. The Company’s lead asset, sotigalimab, is a CD40 agonist with epitope specificity and Fc receptor engagement for optimal therapeutic effect. Its sotigalimab is used for the treatment of Melanoma (post PD-1), Esophageal/GEJ, Sarcoma, Rectal and Ovarian cancers. Its pipeline also includes APX601 and APX801. It has out-licensed five programs for the development of product candidates that were discovered using the APXiMAB platform.